Business

Significant milestone re Thermo Fisher agreement

Significant milestone re Thermo Fisher agreement.

articleVerici Dx PlcJuly 1, 20243/company/verici-dx-plc/news/significant-milestone-re-thermo-fisher-agreement
Significant milestone re Thermo Fisher agreement

About this update from Verici Dx Plc

[{"type":"text","content":"\n\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\") \n \nAchievement of significant milestone under Thermo Fisher Scientific agreement\nSuccessful transfer of pre-transplant prognostic testing technology\n \nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes that Thermo Fisher Scientific has confirmed the completion of the transfer and achievement of all transfer-related activities for the pre-transplant prognostic testing technology licensed by the Company to Thermo Fisher Scientific under the terms of a global licensing and commercialisation agreement announced on 15 November 2023 (the \"Agreement\")1.\n \nThis enables Thermo Fisher Scientific to use the technology to develop a LDT (\"Laboratory Developed Test\") in its own labs. This event triggers a further milestone payment under the Agreement, in line with previously disclosed expectations.\n \nCommenting on the milestone, Sara Barrington, CEO of Verici Dx, said:\n \n\"I am delighted to announce this smooth transition between Verici Dx and Thermo Fisher Scientific. This collaboration brings together Verici Dx's innovative technology into Thermo Fisher's new CLIA laboratory in the U.S., which will ultimately benefit patients and the field of organ transplantation.\"\n \nThis announcement contains inside information for the purposes of Article 7 of the UK Market Abuse Regulation (UK MAR). Upon the publication of this announcement, this inside information is now considered to be in the public domain.\n \n \nEnquiries:\n \n\n\n\n\nVerici Dx\n\n\nwww.vericidx.com\n\n\n \n\n\n\n\nSara Barrington, CEO \n\n\[email protected]\n\n\n \n\n\n\n\nJulian Baines, Chairman\n\n\n \n\n\n \n\n\n\n\n\n\n\n\n\n\n \n\n\n\n\n \n\n\n \n\n\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\n\n\nTel: +44 20 7496 3000\n\n\n \n\n\n\n\nAubrey Powell / Sam Butcher\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \nNotes\n1.     Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/62760\nAbout Verici Dx plc www.vericidx.com\nVerici Dx is a developer of a complementary...

More updates from Verici Dx Plc